Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Nov-Dec;29(6):104578.
doi: 10.1016/j.bjid.2025.104578. Epub 2025 Sep 20.

Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy

Affiliations
Comparative Study

Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy

Juliana Olsen Rodrigues et al. Braz J Infect Dis. 2025 Nov-Dec.

Abstract

Objective: Nucleoside/nucleotide reverse transcriptase inhibitors, particularly tenofovir, can cause long-term side effects such as decreased bone mineral density and estimated glomerular filtration rate. A strategy to mitigate these effects is the simplification of antiretroviral therapy, which involves withdrawing one of the nucleoside/nucleotide reverse transcriptase inhibitors from the therapeutic scheme. While clinical trials and real-world studies have demonstrated that the simplified therapy maintains undetectable viral loads, its impact on bone mineral density and kidney function remains unclear owing to the lack of real-world evidence.

Methods: This retrospective cohort study compared 152 patients who underwent antiretroviral therapy simplification (primarily due to osteopenia, osteoporosis, or decreased estimated glomerular filtration rate) with 306 patients who maintained triple therapy, between April 2013 and September 2022. The simplified regimens included lamivudine plus dolutegravir or ritonavir-boosted darunavir. The groups were analyzed based on their demographic characteristics using Student's t-test in the case of symmetric data. Therapeutic success (undetectable viral load at the end of follow-up) was assessed using Kaplan Meier survival analysis. The estimated glomerular filtration rate variation before and after simplification was analyzed using the Mann-Whitney test. Pre-and post-simplification bone mineral density values were evaluated using the chi-square test for trends and assessed in the simplified therapy group. A significance level of 5% (α = 0.05) was adopted for all tests.

Results: Simplified antiretroviral therapy was non-inferior to triple therapy in maintaining undetectable viral load. Patients receiving simplified regimens showed a positive variation in estimated glomerular filtration rate. A small subset of patients also exhibited improvements in bone mineral density after antiretroviral therapy simplification.

Conclusions: These findings suggest that simplified therapy is as effective as triple therapy and has the additional benefit of reducing tenofovir-related adverse events.

Keywords: HIV; glomerular filtration rate; osteopenia; osteoporosis; simplification; tenofovir.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve illustrating therapeutic success (undetectable viral load) among 458 people living with HIV, comparing simplified and non-simplified antiretroviral regimens. Botucatu, Brazil, 2022.
Fig. 2
Fig. 2
Variation in the estimated glomerular filtration rate among 152 people living with HIV on simplified antiretroviral regimens, categorized by the reason for regimen simplification. Botucatu, Brazil, 2022.

References

    1. De Cock K.M., Jaffe H.W., Curran J.W. Reflections on 40-years of AIDS. Emerg Infect Dis. 2021;27:1553–1560. - PMC - PubMed
    1. Gupta S., Granich R., Williams B.G. Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95-95-95 target. Curr Opin HIV AIDS. 2022;17:368–373. - PubMed
    1. Cahn P., Rolón M.J., Figueroa M.I., Gun A., Patterson P., Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir Lamivudine) study. J Int AIDS Soc. 2017;20 - PMC - PubMed
    1. Shiau S., Arpadi S.M., Yin M.T. Bone update: is it still an issue without tenofovir disoproxil fumarate. Curr HIV/AIDS Rep. 2020;17:1–5. - PMC - PubMed
    1. Wijting I.E., Rokx C., Zillikens M.C., Smits S.A., de Vries-Sluijs T.E., Schurink C.A., et al. Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy. Int J STD AIDS. 2019;30:1042–1048. - PubMed

Publication types

MeSH terms